Ahmed Hanaa H, Shousha Wafaa Gh, El-Mezayen Hatem A, Emara Ibrahim A, Hassan Marwa E
1Hormones Department, National Research Centre, Dokki, Giza, Egypt.
2Biochemistry Department, Faculty of Science, Helwan University, Cairo, Egypt.
Indian J Clin Biochem. 2020 Jan;35(1):54-62. doi: 10.1007/s12291-018-0784-4. Epub 2018 Jul 17.
This study was initiated to explore some novel biomarkers like pro-inflammatory markers (chemerin and visfatin) and anti-inflammatory marker (omentin-1) as prognostic factors for cardiovascular complications in type 2 diabetic patients. Forty diabetic patients without cardiovascular disease, 40 diabetic patients with cardiovascular disease and twenty healthy control counterparts were included in this study. Serum chemerin, omentin-1 and visfatin levels were quantified. Receiver operating characteristic curve analysis was done to identify the cut off value for each marker. The mean serum level of chemerin was 57.65 ± 15.69 ng/l in diabetic patients versus 93.97 ± 26.62 ng/l for the cardio-diabetic ones ( < 0.0001). The mean serum level of omentin-1 was 8.77 ± 1.53 ng/ml in diabetic patients versus 1.76 ± 0.96 ng/ml for the cardio-diabetic ones ( < 0.0001). The mean level of visfatin was 1.44 ± 0.71 ug/l in diabetic patients versus 3.92 ± 3.32 ug/l for the cardio-diabetic ones ( < 0.0001). Chemerin and Visfatin levels were significantly enhanced in the cardio-diabetic patients with increasing C-reactive protein (CRP), triglycerides (TG), fasting blood glucose (FBG), micro-albumin and cholesterol. Omentin-1 level was significantly reduced in the cardio-diabetic patients with increasing CRP, TG, FBG, and cholesterol. It was observed that the area under curve for chemerin, omentin-1and visfatin was 0.877, 0.998 and 0.735, respectively. In conclusion, this study evidences that the measuring serum levels of chemerin, omentin-1 and visfatin may help in the prognosis of cardiovascular complications in type 2 diabetic patients.
本研究旨在探索一些新型生物标志物，如促炎标志物（chemerin和内脂素）和抗炎标志物（网膜素-1），作为2型糖尿病患者心血管并发症的预后因素。本研究纳入了40例无心血管疾病的糖尿病患者、40例有心血管疾病的糖尿病患者和20例健康对照者。对血清chemerin、网膜素-1和内脂素水平进行了定量分析。采用受试者工作特征曲线分析来确定每种标志物的临界值。糖尿病患者chemerin的平均血清水平为57.65±15.69 ng/l，而心血管疾病合并糖尿病患者为93.97±26.62 ng/l（<0.0001）。糖尿病患者网膜素-1的平均血清水平为8.77±1.53 ng/ml，而心血管疾病合并糖尿病患者为1.76±0.96 ng/ml（<0.0001）。糖尿病患者内脂素的平均水平为1.44±0.71 ug/l，而心血管疾病合并糖尿病患者为3.92±3.32 ug/l（<0.0001）。心血管疾病合并糖尿病患者的chemerin和内脂素水平随着C反应蛋白（CRP）、甘油三酯（TG）、空腹血糖（FBG）、微量白蛋白和胆固醇的升高而显著升高。心血管疾病合并糖尿病患者的网膜素-1水平随着CRP、TG、FBG和胆固醇的升高而显著降低。观察到chemerin、网膜素-1和内脂素的曲线下面积分别为0.877、0.998和0.735。总之，本研究证明，检测血清chemerin、网膜素-1和内脂素水平可能有助于2型糖尿病患者心血管并发症的预后评估。
